TI
NGM

Trexquant Investment’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Trexquant Investment’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-35,245
Closed -$461K – 1815
2022
Q3 		$461K Buy
+35,245
New +$534K 0.02% 847
2022
Q2 		– Sell
-25,147
Closed -$383K – 1957
2022
Q1 		$383K Buy
25,147
+6,638
+36% +$104K 0.02% 893
2021
Q4 		$328K Sell
18,509
-8,622
-32% -$165K 0.02% 865
2021
Q3 		$570K Buy
+27,131
New +$597K 0.05% 484

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Trexquant Investment's NGM Position: Q4 2022 in Review

Trexquant Investment sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2022, closing a stake of 35,245 shares — an estimated $461K sold.

Trexquant Investment first reported a position in NGM in Q3 2021 and held it in 4 quarters. The position peaked at $570K in Q3 2021. 125 funds tracked by Wall St. Rank hold NGM as of Q4 2022.

  • Trexquant Investment reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Trexquant Investment sold 35,245 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $461K.
  • Trexquant Investment first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 4 quarters.
  • Trexquant Investment's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $570K in Q3 2021.
  • 125 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Trexquant Investment's 13F filing for Q4 2022, filed 13 Feb 2023.